Scholars@Duke
Louis Frederic Diehl

Louis Frederic Diehl

Professor Emeritus of Medicine
Medicine, Hematologic Malignancies and Cellular Therapy
louis.diehl@duke.edu
DUMC Box 3961, Durham, NC 27710
2400 Pratt St Suite 5000, DUMC Box 3961, Durham, NC 27710

Scholarly Works

A 79-Year-Old Female Patient With Altered Mental Status and Anemia.

Journal article Arthritis Care Res (Hoboken) · April 2022 Full text Link to item Cite

Phase II Study of Single-Agent and Combination Everolimus and Panobinostat in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

Journal article Cancer Invest · November 2021 Novel therapeutics are needed for patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL). Everolimus is an mTOR pathway inhibitor with synergistic anti-tumor activity when combined with histone deacetylase inhibitors, such as panobi ... Full text Link to item Cite

Microtransplantation in older patients with AML: A pilot study of safety, efficacy and immunologic effects.

Journal article Am J Hematol · June 2020 Older AML patients have low remission rates and poor survival outcomes with standard chemotherapy. Microtransplantation (MST) refers to infusion of allogeneic hematopoietic stem cells without substantial engraftment. MST has been shown to improve clinical ... Full text Link to item Cite

Pre-transplant hepatic steatosis (fatty liver) is associated with chronic graft-vs-host disease but not mortality.

Journal article PLoS One · 2020 Allogeneic-HCT (allo-HCT), while potentially curative, can result in significant complications including graft versus host disease (GVHD). Prior studies suggest that metabolic syndrome may be one risk factor for GVHD. We hypothesized that hepatic steatosis ... Full text Link to item Cite

Phase 2 Study of Dose-Reduced Consolidation Radiation Therapy in Diffuse Large B-Cell Lymphoma.

Journal article Int J Radiat Oncol Biol Phys · September 1, 2019 PURPOSE: To evaluate the feasibility of reducing the dose of consolidation radiation therapy (RT) in diffuse large B-cell lymphoma. METHODS AND MATERIALS: This phase 2 study enrolled patients with diffuse large B-cell lymphoma, not otherwise specified and ... Full text Link to item Cite

Phase I Study of the Combination of Bendamustine, Rituximab, and Pixantrone in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma.

Journal article Clin Lymphoma Myeloma Leuk · October 2018 BACKGROUND: For patients with aggressive lymphomas who relapse after initial therapy, a durable response is rarely achieved with standard salvage therapies. Significant efforts have focused on the development of novel treatments with reduced toxicity. We c ... Full text Link to item Cite

Phase I/II dose expansion of a trial investigating bendamustine and pomalidomide with dexamethasone (BPd) in patients with relapsed/refractory multiple myeloma.

Conference Journal of Clinical Oncology · May 20, 2017 8008 Background: The combination of bendamustine, pomalidomide, and dexamethasone (BPd) displays promising activity in heavily pretreated RRMM. In the Phase I portion, MTD was 120 mg/m2bendamustine/3mg pomali ... Full text Cite

A Phase I-II Study of the Combination of Bendamustine and Pomalidomide with Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma.

Conference Blood · December 3, 2015 AbstractBackgroundBendamustine, a bifunctional mechlorethamine derivative with alkylating properties and pomalidomide, an IMiD® immunomodulatory agent, have both demonstrated ... Full text Cite

(18)F-fluorodeoxyglucose-positron emission tomography/computed tomography after one cycle of chemotherapy in patients with diffuse large B-cell lymphoma: results of a Nordic/US intergroup study.

Journal article Leuk Lymphoma · July 2015 We evaluated the predictive value of interim positon emission tomography (I-PET) after one course of chemoimmunotherapy in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL). One hundred and twelve patients with DLBCL were enrolled. All pa ... Full text Link to item Cite

Low-dose consolidation radiation therapy for early stage unfavorable Hodgkin lymphoma.

Journal article Int J Radiat Oncol Biol Phys · May 1, 2015 PURPOSE: The German Hodgkin Study Group (GHSG) trial HD11 established 4 cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) and 30 Gy of radiation therapy (RT) as a standard for early stage (I, II), unfavorable Hodgkin lymphoma (HL). Addi ... Full text Link to item Cite

Peripheral T-cell lymphoma, NOS, and anaplastic large cell lymphoma.

Journal article Hematology Am Soc Hematol Educ Program · 2015 Peripheral T-cell lymphomas (PTCL), with the exception of anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL), have a very poor prognosis. Although current first line chemotherapy continues to be a CHOP-like (cyclophosphamide, d ... Full text Link to item Cite

Atypical Primary Effusion Lymphoma In A Lung Transplant Recipient

Conference AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE · January 1, 2015 Link to item Cite

Improving outcomes in advanced DLBCL: systemic approaches and radiotherapy.

Journal article Oncology (Williston Park) · December 2014 Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma. Approximately half of patients will present with advanced (stage III/IV) disease. The cornerstone of treatment is a combination of chemotherapy and immunotherapy, mos ... Link to item Cite

In vivo treatment sensitivity testing with positron emission tomography/computed tomography after one cycle of chemotherapy for Hodgkin lymphoma.

Journal article J Clin Oncol · September 1, 2014 PURPOSE: Negative [(18)F]fluorodeoxyglucose (FDG) -positron emission tomography (PET)/computed tomography (CT) after two cycles of chemotherapy indicates a favorable prognosis in Hodgkin lymphoma (HL). We hypothesized that the negative predictive value wou ... Full text Link to item Cite

Phase II open label study of the oral vascular endothelial growth factor-receptor inhibitor PTK787/ZK222584 (vatalanib) in adult patients with refractory or relapsed diffuse large B-cell lymphoma.

Journal article Leuk Lymphoma · December 2013 PTK787/ZK222584 (vatalanib), an orally active inhibitor of vascular endothelial growth factor receptors (VEGFRs), was evaluated in this phase II study of 20 patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Patients received once-dai ... Full text Link to item Cite

A Phase I study of arsenic trioxide (Trisenox), ascorbic acid, and bortezomib (Velcade) combination therapy in patients with relapsed/refractory multiple myeloma.

Journal article Cancer Invest · March 2013 PURPOSE: This Phase I study assessed the feasibility of concomitant arsenic trioxide (ATO), ascorbic acid (AA), and bortezomib (Velcade™) (AAV) for patients with relapsed/refractory multiple myeloma. EXPERIMENTAL DESIGN: ATO (0.25 mg/kg) and AA (1 g) were ... Full text Link to item Cite

Re-induction therapy decisions based on day 14 bone marrow biopsy in acute myeloid leukemia.

Journal article Leuk Res · January 2013 PURPOSE: The decision to re-induce patients with acute myeloid leukemia (AML) based on results of the day 14 bone marrow (BM) biopsy is variable and lacks evidence based data. The aim of our review was to evaluate the accuracy of a day 14 BM biopsy in dete ... Full text Link to item Cite

Chronic lymphocytic leukemia and regulatory B cells share IL-10 competence and immunosuppressive function.

Journal article Leukemia · January 2013 Chronic lymphocytic leukemia (CLL) can be immunosuppressive in humans and mice, and CLL cells share multiple phenotypic markers with regulatory B cells that are competent to produce interleukin (IL)-10 (B10 cells). To identify functional links between CLL ... Full text Link to item Cite

Combined-modality therapy for early-stage Hodgkin lymphoma: maintaining high cure rates while minimizing risks.

Journal article Oncology (Williston Park) · December 2012 Multiple randomized studies have demonstrated that chemotherapy, most commonly ABVD (doxorubicin [Adriamycin], bleomycin, vinblastine, dacarbazine), followed by consolidation radiation therapy is the most effective treatment program for early-stage Hodgkin ... Link to item Cite

Phase II Study of VEGF Inhibitor, PTK787/ZK222584, in Patients with Refractory or Relapsed Diffuse Large B-Cell Lymphoma

Conference Blood · November 16, 2012 AbstractAbstract 1626Background:Diffuse Large B-cell Lymphoma (DLBCL) patients with primary refractor ... Full text Cite

Pilot Study of Sorafenib for Myelodysplastic Syndrome

Conference Blood · November 16, 2012 AbstractAbstract 4948Background:MDS (Myelodysplastic syndrome) is a hematologic malignancy in which o ... Full text Cite

Phase 1 Study of Lenalidomide and Decitabine for High and Intermediate 2 Risk MDS

Conference Blood · November 16, 2012 AbstractAbstract 4935Background:Myelodysplasticsyndromes (MDS) are a heterogeneous group of hematopoi ... Full text Cite

Impact of consolidation radiation therapy in stage III-IV diffuse large B-cell lymphoma with negative post-chemotherapy radiologic imaging.

Journal article Int J Radiat Oncol Biol Phys · November 1, 2012 PURPOSE: While consolidation radiation therapy (i.e., RT administered after chemotherapy) is routine treatment for patients with early-stage diffuse large B-cell lymphoma (DLBCL), the role of consolidation RT in stage III-IV DLBCL is controversial. METHODS ... Full text Link to item Cite

Phase I study of dose dense induction and consolidation with gemtuzumab ozogamicin and high dose cytarabine in older adults with AML

Journal article Journal of Geriatric Oncology · July 1, 2012 Objective: Older adults with acute myeloid leukemia (AML) tend to have worse complete remission (CR) rates and overall survival compared to their younger counterparts. At least one reason for this is increased expression of the multidrug resistance gene (M ... Full text Cite

Phase II study of cenersen, an antisense inhibitor of p53, in combination with fludarabine, cyclophosphamide and rituximab for high-risk chronic lymphocytic leukemia.

Journal article Leuk Lymphoma · February 2012 Patients with chronic lymphocytic leukemia (CLL) with deletion or mutation of TP53 have exceedingly poor clinical outcomes. Cenersen, an oligonucleotide targeting TP53, has been shown to abrogate the activity of TP53 gain-of-function mutants and to increas ... Full text Link to item Cite

Combined-modality therapy for early-stage Hodgkin lymphoma: Maintaining high cure rates while minimizing risks

Journal article Oncology United States · January 1, 2012 Multiple randomized studies have demonstrated that chemotherapy, most commonly ABVD (doxorubicin [Adriamycin], bleomycin(Drug information on bleomycin), vinblastine(Drug information on vinblastine), dacarbazine(Drug information on dacarbazine)), followed b ... Cite

SET oncoprotein overexpression in B-cell chronic lymphocytic leukemia and non-Hodgkin lymphoma: a predictor of aggressive disease and a new treatment target.

Journal article Blood · October 13, 2011 B-cell chronic lymphocytic leukemia (CLL), an incurable leukemia, is characterized by defective apoptosis. We found that the SET oncoprotein, a potent inhibitor of the protein phosphatase 2A (PP2A) tumor suppressor, is overexpressed in primary CLL cells an ... Full text Link to item Cite

The impact of radiation therapy in patients with diffuse large B-cell lymphoma with positive post-chemotherapy FDG-PET or gallium-67 scans.

Journal article Ann Oncol · February 2011 BACKGROUND: 2-[fluorine-18]fluoro-2-deoxy-D-glucose-positron emission tomography (PET) and gallium-67 citrate (gallium) response after chemotherapy are powerful prognostic factors in diffuse large B-cell lymphoma (DLBCL). However, clinical outcomes when co ... Full text Link to item Cite

A Phase II trial of gemcitabine and mitoxantrone for patients with acute myeloid leukemia in first relapse.

Journal article Clin Lymphoma Myeloma Leuk · December 2010 INTRODUCTION: We evaluated the complete remission (CR) rate in patients with acute myeloid leukemia (AML) in first relapse treated with fixed-dose-rate gemcitabine and mitoxantrone. In addition, we measured multidrug resistance (MDR) proteins on pretreatme ... Full text Link to item Cite

Radiation therapy in the management of diffuse large B-cell lymphoma: still relevant?

Journal article Oncology (Williston Park) · November 30, 2010 Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma in the United States. Historically, radiation therapy (RT) was the primary treatment for patients with localized disease. Several randomized trials have demonstrated t ... Link to item Cite

Radiation therapy in the management of diffuse large B-cell lymphoma: still relevant?

Journal article Oncology (Williston Park, N.Y.) · November 30, 2010 Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma in the United States. Historically, radiation therapy (RT) was the primary treatment for patients with localized disease. Several randomized trials have demonstrated t ... Cite

LMP-420: a novel purine nucleoside analog with potent cytotoxic effects for CLL cells and minimal toxicity for normal hematopoietic cells.

Journal article Leukemia · September 2010 B-cell chronic lymphocytic leukemia (CLL) is characterized by slow accumulation of malignant cells, which are supported in the microenvironment by cell-cell interactions and soluble cytokines such as tumor necrosis factor (TNF). We evaluated the effect of ... Full text Link to item Cite

Overcoming drug resistance in mantle cell lymphoma using a combination of dose-dense and intense therapy.

Journal article Cancer Invest · July 2010 We present a study of the prevalence of genetic polymorphisms and expression of genes encoding the drug-resistance proteins glutathione S-transferases (GSTs) in order to gain insights into the pattern of failure evident in mantle cell lymphoma. We note a h ... Full text Link to item Cite

"Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma.

Journal article Biol Blood Marrow Transplant · January 2010 The purpose of this study was to evaluate the efficacy and safety of short-course bortezomib, melphalan, prednisone (VMP) in previously untreated multiple myeloma as frontline therapy for transplant-ineligible patients and induction prior to autologous ste ... Full text Link to item Cite

A genomic approach to improve prognosis and predict therapeutic response in chronic lymphocytic leukemia.

Journal article Clin Cancer Res · November 15, 2009 PURPOSE: Chronic lymphocytic leukemia (CLL) is a B-cell malignancy characterized by a variable clinical course. Several parameters have prognostic capabilities but are associated with altered response to therapy in only a small subset of patients. EXPERIME ... Full text Link to item Cite

T cell large granular lymphocyte leukemia associated with rheumatoid arthritis and neutropenia.

Journal article Clin Immunol · August 2009 T cell large granular lymphocyte leukemia (T-LGL) is a disease characterized by clonal expansion of cytotoxic T cells (CTLs). It generally follows an indolent course and is notable for an association with chronic inflammation, neutropenia and rheumatoid ar ... Full text Link to item Cite

Outcomes of patients who undergo aggressive induction therapy for secondary acute myeloid leukemia.

Journal article Cancer · July 1, 2009 BACKGROUND: Response and survival in 96 patients with secondary acute myeloid leukemia (sAML) who received aggressive induction chemotherapy was reviewed. METHODS: The median follow-up of survivors was 2.3 years. A total of 70 (73%) patients achieved a mor ... Full text Link to item Cite

Apolipoprotein E genotype as a determinant of survival in chronic lymphocytic leukemia.

Journal article Leukemia · December 2008 Survival of chronic lymphocytic leukemia (CLL) cells requires sustained activation of the antiapoptotic PI-3-K/Akt pathway, and many therapies for CLL cause leukemia cell death by triggering apoptosis. Blood lipoprotein particles are either pro- or antiapo ... Full text Link to item Cite

Clinical and molecular predictors of disease severity and survival in chronic lymphocytic leukemia.

Journal article Am J Hematol · December 2007 Several parameters may predict disease severity and overall survival in chronic lymphocytic leukemia (CLL). The purpose of our study of 190 CLL patients was to compare immunoglobulin heavy chain variable region (IgV(H)) mutation status, cytogenetic abnorma ... Full text Link to item Cite

Systemic interleukin-2 and adoptive transfer of lymphokine-activated killer cells improves antibody-dependent cellular cytotoxicity in patients with relapsed B-cell lymphoma treated with rituximab.

Journal article Clin Cancer Res · April 15, 2007 PURPOSE: Murine models have shown that antibody-dependent cellular cytotoxicity (ADCC) can be improved with addition of lymphokine-activated killer (LAK) cells to monoclonal antibodies. A pilot trial of rituximab and LAK cells in patients with rituximab-re ... Full text Link to item Cite

A phase I/II study examining pentostatin, chlorambucil, and theophylline in patients with relapsed chronic lymphocytic leukemia and non-Hodgkin's lymphoma.

Journal article Ann Hematol · May 2006 In an attempt to exploit bcl-2 overexpression and aberrant p53 function, two frequently encountered aberrations that predict marked treatment resistance and worse prognosis in patients with chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma (NHL ... Full text Link to item Cite

Phase I study of low-dose interleukin-2, fludarabine, and cyclophosphamide for previously untreated indolent lymphoma and chronic lymphocytic leukemia.

Journal article Clin Cancer Res · December 1, 2005 PURPOSE: Fludarabine and cyclophosphamide is an effective combination but increases the risk of opportunistic infections due to depressed lymphocyte counts. In an attempt to preserve CD4 counts, we conducted a phase I, double-blind, placebo-controlled tria ... Full text Link to item Cite

Requirement for myeloid growth factors in the differentiation of acute promyelocytic leukaemia.

Journal article Br J Haematol · March 2005 It is well known that the differentiation of acute promyelocytic leukaemia (APL) cells by all-trans-retinoic acid (ATRA) may be enhanced by myeloid growth factors, but the requirement for growth factors in this process is unclear. Our previous studies in m ... Full text Link to item Cite

Outcomes of autologous and allogeneic blood or marrow transplantation for mantle cell lymphoma.

Journal article Biol Blood Marrow Transplant · January 2005 To evaluate high-dose therapy and autologous or allogeneic blood or marrow transplantation (BMT) for mantle cell lymphoma, patients receiving BMT for newly diagnosed or relapsed mantle cell lymphoma were identified through the registry at Johns Hopkins. Th ... Full text Link to item Cite

Long-term follow-up of T cell-depleted allogeneic bone marrow transplantation in refractory multiple myeloma: importance of allogeneic T cells.

Journal article Biol Blood Marrow Transplant · May 2003 Multiple myeloma may be cured by myeloablative conditioning and allogeneic blood or marrow transplantation (alloBMT), but this occurs at the expense of high transplant-related mortality. In an endeavor to reduce procedure-related toxicity, this study retro ... Full text Link to item Cite

Leukemia cutis in a patient with chronic neutrophilic leukemia.

Journal article J Am Acad Dermatol · February 2001 Chronic neutrophilic leukemia (CNL) is a rare myeloproliferative disorder. Less than 50 cases have been reported. We report the first case of CNL with an associated leukemia cutis. CNL was diagnosed in a 74-year-old white woman in 1998, based on neutrophil ... Full text Link to item Cite

Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies.

Journal article Blood · July 1, 2000 To evaluate the response rate and potential toxicities, a phase II trial was conducted of fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated low-grade and select intermediate-grade lymphoid malignancies. Symptoma ... Link to item Cite

A dose-finding study of liposomal daunorubicin with CVP (COP-X) in advanced NHL.

Journal article Ann Oncol · June 2000 BACKGROUND: Standard therapy for lymphoma consists of a cyclophosphamide (C), doxorubicin, vincristine (V), and prednisone (P) (CHOP) combination regimen. Liposomal daunorubicin (DaunoXome) is an alternative to doxorubicin for patients with lymphoma becaus ... Full text Link to item Cite

Life expectancy benefits of cancer screening in the end-stage renal disease population.

Journal article Am J Kidney Dis · February 2000 Health maintenance includes secondary prevention through cancer screening. There are no established guidelines for cancer screening patients with end-stage renal disease (ESRD). Using an established method of estimating life expectancy, published literatur ... Full text Link to item Cite

The American College of Surgeons Commission on Cancer and the American Cancer Society. The National Cancer Data Base report on age, gender, treatment, and outcomes of patients with chronic lymphocytic leukemia.

Journal article Cancer · December 15, 1999 BACKGROUND: The natural history of chronic lymphocytic leukemia (CLL) is changing, although the reasons (potential changes in the disease's biology or in patterns in patient characteristics, treatment, or referral) are unclear. METHODS: This report uses Na ... Link to item Cite

Herpes virus infections occur frequently following treatment with fludarabine: results of a prospective natural history study.

Journal article Br J Haematol · May 1999 We performed a prospective infectious natural history study of 21 patients with low-grade lymphoproliferative disorders receiving fludarabine as initial (n = 5) or salvage (n = 16) therapy. 12 (57%) of these patients developed herpes zoster (n = 9), herpes ... Link to item Cite

D-dimer assay predicts mortality in critically ill patients without disseminated intravascular coagulation or venous thromboembolic disease.

Journal article Intensive Care Med · February 1999 OBJECTIVE: To determine if D-dimer predicts outcomes in critically ill patients. DESIGN: Observational, cohort study. SETTING: Medical intensive care unit (MICU) of a tertiary care hospital. PATIENTS AND PARTICIPANTS: Seventy-four patients consecutively ad ... Full text Link to item Cite

Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53.

Journal article Blood · November 15, 1998 Flavopiridol has been reported to induce apoptosis in lymphoid cell lines via downregulation of bcl-2. The in vitro activity of flavopiridol against human chronic lymphocytic leukemia (CLL) cells and potential mechanisms of action for inducing cytotoxicity ... Link to item Cite

Hemolytic anemia after fludarabine therapy for chronic lymphocytic leukemia.

Journal article J Clin Oncol · May 1998 PURPOSE: A report of the clinical features, treatment, and outcome of patients who developed hemolytic anemia (HA) temporally associated with fludarabine (Fludara; Berlex Laboratories, Richmond, CA) therapy for chronic lymphocytic leukemia (CLL). PATIENTS ... Full text Link to item Cite

Comparison of psychosocial adaptation of advanced stage Hodgkin's disease and acute leukemia survivors. Cancer and Leukemia Group B.

Journal article Ann Oncol · March 1998 BACKGROUND: The purpose of this study was to compare the long-term psychosocial adaptation of Hodgkin's disease and adult acute leukemia survivors. PATIENTS AND METHODS: Two hundred seventy-three Hodgkin's disease (HD) and 206 adult acute leukemia (AL) sur ... Full text Link to item Cite

Transient abnormalities in serum bilirubin and lactate dehydrogenase levels following red blood cell transfusions in adults.

Journal article Am J Med · February 1998 BACKGROUND: The effect of transfusion of small amounts of packed red blood cells (PRBC) on serum chemistry values is not known. METHODS: We studied 73 adult patients without evidence of bleeding who received 2-unit PRBC transfusions. In study 1 (n=39), we ... Full text Link to item Cite

Autoimmune disease and chronic lymphocytic leukemia: autoimmune hemolytic anemia, pure red cell aplasia, and autoimmune thrombocytopenia.

Journal article Semin Oncol · February 1998 Immune dysregulation, a hallmark of chronic lymphocytic leukemia (CLL), manifests itself in three autoimmune diseases: warm autoimmune hemolytic anemia (AIHA); idiopathic thrombocytopenia (ITP); and, pure red cell aplasia (PRCA). AIHA occurs in 11% of adva ... Link to item Cite

Detection of Epstein-Barr virus in transformations of low-grade B-cell lymphomas after fludarabine treatment.

Journal article Mod Pathol · November 1997 Fludarabine is a highly effective chemotherapeutic agent for chronic lymphocytic leukemia/small lymphocytic lymphoma and is also active in other B-cell lymphoproliferative disorders. Although highly efficacious in destroying the malignant B-cells, fludarab ... Link to item Cite

Hodgkin's disease treated with neck radiation is associated with increased antibody-dependent cellular cytotoxicity against human extraocular muscle cells.

Journal article Thyroid · June 1997 Patients with Hodgkin's disease have higher a prevalence of thyroid function abnormalities and, perhaps, orbitopathy than the general population, but the pathophysiology of this association and its relationship to Hodgkin's disease treatment remain unclear ... Full text Link to item Cite

Hemolytic anemia and cancer.

Journal article Cancer Treat Rev · January 1996 Full text Link to item Cite

Opportunistic pulmonary infections with fludarabine in previously treated patients with low-grade lymphoid malignancies: a role for Pneumocystis carinii pneumonia prophylaxis.

Journal article Am J Hematol · June 1995 The high incidence of opportunistic pulmonary infections in fludarabine-treated patients at Walter Reed Army Medical Center (WRAMC) and in the literature are described. A CancerLit search of fludarabine from June 1983-April 1994 with subsequent cross refer ... Full text Link to item Cite

Mean platelet volume improves upon the megathrombocyte index but cannot replace the blood film examination in the evaluation of thrombocytopenia.

Journal article Am J Hematol · October 1993 The measurement of the number of platelets larger than 3 microns (megathrombocyte index) is the first element in the evaluation of thrombocytopenia. This is currently performed by counting the number of large platelets on the peripheral blood film. The MPV ... Full text Link to item Cite

In Reply

Journal article Archives of Internal Medicine · January 1, 1992 Full text Cite

Congenital neutropenia: How low? [1]

Journal article Archives of Internal Medicine · 1992 Cite

Radiation and chemotherapy in the treatment of esophageal cancer.

Journal article Gastroenterol Clin North Am · December 1991 Patients with esophageal cancer present with a cancer that is locally aggressive in a critical area and that readily metastasizes. Neither surgery nor radiotherapy alone can control local disease, and chemotherapy alone cannot control local or disseminated ... Link to item Cite

Mediastinal bulk in Hodgkin disease. Method of measurement versus prognosis.

Journal article Invest Radiol · December 1991 The presence of a large mediastinal mass (bulk disease) in patients with newly diagnosed Hodgkin disease is believed by many to predict a poorer prognosis and to warrant more aggressive treatment. These masses are formed by an aggregate of mediastinal lymp ... Full text Link to item Cite

Leukopenia, neutropenia, and reduced hemoglobin levels in healthy American blacks.

Journal article Arch Intern Med · March 1991 Hematologic profiles of 462 persons, mostly active-duty service members, were studied to determine whether hematologic differences between blacks and whites exist in a healthy population. Whites had significantly greater mean concentrations of leukocytes ( ... Link to item Cite

The pattern of intrathoracic Hodgkin's disease assessed by computed tomography.

Journal article J Clin Oncol · March 1991 Computed tomography (CT) was used to define the sites of intrathoracic abnormality in Hodgkin's disease, determine a pattern of progression of disease in the thorax, and establish the place of this pattern of spread in the differential diagnosis of thoraci ... Full text Link to item Cite

The significance of necrotic mediastinal lymph nodes on CT in patients with newly diagnosed Hodgkin disease.

Journal article AJR Am J Roentgenol · August 1990 Necrosis in lymph nodes shown on CT in many patients with nodal metastases may indicate that the primary tumor is aggressive and has a high degree of malignancy. However, the significance of nodal necrosis in patients with mediastinal Hodgkin disease remai ... Full text Link to item Cite

Enlargement of mediastinal masses on simulation films: a radiotherapeutic problem in the management of patients with Hodgkin's disease.

Journal article Med Pediatr Oncol · 1990 The size of the mediastinal mass on standard posterior-anterior chest radiograph in stage I and stage II Hodgkin's disease has both prognostic and therapeutic importance. But the actual treatment is based on the anterior-posterior supine simulation film. P ... Full text Link to item Cite

Trephine needle bone marrow biopsy in the initial staging of Hodgkin disease: sensitivity and specificity of the Ann Arbor staging procedure criteria.

Journal article Am J Hematol · March 1989 The purpose of this study was to test the value of the Ann Arbor staging procedures committee criteria in defining a group of newly diagnosed patients with Hodgkin disease who do not have involvement of the bone marrow and do not need this procedure perfor ... Full text Link to item Cite

RE: Hodgkin disease Clinical utility of CT in initial staging and treatment

Journal article Investigative Radiology · January 1, 1989 Cite

Does review of peripheral blood smears help in the initial workup of common anemias?

Journal article J Gen Intern Med · 1989 Sixty-five physicians were tested to determine the effect of their reviews of red blood cell morphology on their subsequent diagnoses of and workup plans for common anemias. The subjects read clinical and laboratory data for six pairs of cases of anemia, r ... Full text Link to item Cite

Hodgkin disease: clinical utility of CT in initial staging and treatment.

Journal article Radiology · October 1988 One hundred seven consecutive new cases of Hodgkin disease were evaluated with chest radiography and computed tomography (CT) for initial staging. The data were evaluated with regard to five popular treatment protocols for Hodgkin disease. Thoracic CT scan ... Full text Link to item Cite

Hematologic indexes in men attending an infertility clinic.

Journal article Arch Androl · 1988 To assess whether oligospermia in infertile men might be associated with abnormalities of another rapidly dividing cell population, namely, blood cells, we studied retrospectively hematologic indexes in 72 unselected men initially attending an infertility ... Full text Link to item Cite

Fatal esorubicin-induced cardiomyopathy: report of a case and review of the literature.

Journal article Cancer Chemother Pharmacol · 1988 A case of fatal dilated cardiomyopathy induced by esorubicin (ESO) at a total dose of 740 mg/m2, given in 27 doses over 650 days, is reported. The sudden onset, rapid clinical deterioration, and fatal outcome are detailed. The outcome was not predicted by ... Full text Link to item Cite

A comparison of randomized concurrent control groups with matched historical control groups: are historical controls valid?

Journal article J Clin Oncol · July 1986 The use of a historical control group is predicated on the assumption that survival and relapse-free survival in the historical control group closely approximate the survival and relapse-free survival in a randomized concurrent control group. This assumpti ... Full text Link to item Cite

Changes in criteria for tumor response.

Journal article J Clin Oncol · February 1985 Full text Link to item Cite

Skin metastases confined to a field of previous irradiation. Report of two cases and review of the literature.

Journal article Cancer · May 1, 1984 Two cases of tumor recurrence within a previously irradiated skin area are reported. Typical lesions evolve from an erythematous base and progress to induration and tumor papules. A review of clinical literature indicates that irradiation does not increase ... Full text Link to item Cite

Ambulatory use of high-dose intravenous morphine for severe pain.

Journal article Drug Intell Clin Pharm · February 1984 A case is presented that describes the use of an intravenous morphine infusion to treat severe pain in an outpatient setting. The patient had severe pain secondary to tumor involvement of the brachial plexus. Morphine was administered as a concentrated sol ... Full text Link to item Cite

Radiation as salvage therapy for patients with Hodgkin's disease relapsing after MOPP (mechlorethamine, vincristine, prednisone, and procarbazine) chemotherapy.

Journal article Cancer Treat Rep · September 1983 Six patients with Hodgkin's disease who failed MOPP (mechlorethamine, vincristine, prednisone, and procarbazine) chemotherapy, with recurrences confined to lymph node areas, are reported. All patients were treated with tumoricidal doses of irradiation in m ... Link to item Cite

Metastatic thymoma with myasthenia gravis: complete remission with combination chemotherapy.

Journal article Cancer · August 1, 1982 A 29-year-old male developed myasthenia gravis 29 months after resection of a "benign" mediastinal thymoma. Metastatic thymoma was found in the pleura 45 months after the initial surgical resection. Combination chemotherapy with cyclophosphamide and doxoru ... Full text Link to item Cite

Increased heat sensitivity of red blood cells in hereditary elliptocytosis with acquired cobalamin (vitamin B12) deficiency.

Journal article Blood · June 1982 Structural membrane proteins were studied from erythrocytes (RBC) of a patient with a nonhemolytic form of hereditary elliptocytosis (HE) who developed a microcytic anemia with fragmented RBC while cobalamin (B12) deficient. Evidence is presented for quali ... Link to item Cite

Gamma (immune) interferon production by leukocytes from a patient with a TG cell proliferative disease.

Journal article Blood · January 1982 We report a patient with a disease characterized by proliferation of T cells with Fc receptors for IgG (TG). However, unlike lymphoid cells from normal individuals or from patients with other lymphoid malignancies, the patient's lymphocytes spontaneously p ... Link to item Cite

Radiation as salvage therapy for patients with Hodgkin's disease (HD) relapsing after MOPP chemotherapy

Journal article Proceedings of the American Society of Clinical Oncology · January 1, 1982 Cite